Efficacy of the Heat-Labile Enterotoxin from Escherichia Coli as an Adjuvant for a HSV-2 Inactivated Oral Vaccine
Abstract
This project examined the efficacy of the heat-labile enterotoxin from Escherichia coli (LT) as an adjuvant for an inactivated HSV-2 vaccine. Using 5-week-old BAB/c mice, three oral doses of inactivated HSV-2/LT (25 ug/25 ug) vaccine given at weekly intervals were ineffective in protecting mice from infection. Administering the second booster of vaccine intravaginally (IVAG) or reducing the dose of LT (10 ug) did not increase the efficacy of the vaccine. This lack of response to the vaccine was not age-related as 8-week-old mice gave similar results, even when the primary vaccination was given IVAG. Finally, we tested different doses of inactivated HSV-2 in a protocol which included an oral vaccination on day 0 and 7 with 10 ug LT and either I ug, 5 ug, or 10 ug inactivated HSV-2. This was followed by an IVAG booster on day 14. Our results showed significant protection (P <0.05) in the 10 ug HSV-2/LT treated group as evidenced by increased survival and decreased vaginal HSV-2 titers.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 31, 1996
- Accession Number
- ADA312064
Entities
People
- Angelo J. Pinto